The COVID-19 pandemic increased the incidence of newly diagnosed cancers: evidence from a large cohort study in Southern Italy.

Publication date: Jul 01, 2025

Recent studies based on hospital and outpatient clinic databases have reported a decline in cancer diagnoses during the COVID-19 pandemic, an observation that has been mainly attributed to halted screenings. We investigated the impact of COVID-19 on cancer incidence in the Campania Region (Italy) among adults followed by their primary care physicians over a 6-year period (2017-2022). Using a single-cohort design, we employed interrupted time series (ITS) analysis to compare cancer incidence rates during the 3 years preceding the pandemic (2017-2019) with those during the three pandemic years (2020-2022). We analyzed data from 212,656 individuals and found that the incidence of new cancer diagnoses rose from 14. 3 to 23. 1 per 1000 person-years when comparing the pre-pandemic to the COVID-19 period. ITS analysis revealed a stable trend in cancer diagnoses before the pandemic, followed by a marked increase of ~8 new cases per month beginning in January 2020, with a peak observed in August 2021. Notably, diagnoses of brain and skin cancers increased by 300% in 2022 compared to 2017. Taken together, these findings highlight a concerning increase in cancer diagnoses in the Campania Region during the COVID-19 pandemic, contrasting with earlier reports that pointed to a decline in cases, mostly attributed to interrupted screening services. Several indirect factors might contribute to this trend, including heightened psychosocial stress and shifts in lifestyle behaviors, as well as profound disruptions in access to and continuity of healthcare delivery.

Open Access PDF

Concepts Keywords
Cancers Adult
Italy Aged
Month Clinical research
Outpatient Cohort Studies
COVID-19
COVID-19
Epidemiology
Female
Humans
Incidence
Infectious disorders
Italy
Male
Middle Aged
Neoplasms
Oncology
Pandemic
Pandemics
Real world data
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH cancers
disease MESH skin cancers
disease MESH lifestyle
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH hypertension
disease MESH dyslipidemia
disease MESH viral infections
disease MESH infections
drug DRUGBANK Nonoxynol-9
disease MESH chronic conditions
disease MESH emergency
disease MESH death
disease IDO history

Original Article

(Visited 6 times, 1 visits today)